

# Subject Index

- Abl 141
- , c- 145, 160, 163
- , protein tyrosin kinase 149
- Acute leukemia
  - see leukemia
- Agarose microbeats, cell encapsulation 299
- AIDS 43, 404, 414, 430, 434, 436
  - , chemotherapy in 47
  - , hematopoietic progenitor cells in 176
- ALL 37, 57, 67, 145, 160
  - see also leukemia
  - , bone marrow transplantation for 68
  - , Ph<sup>+</sup> 149
- Alu repeat 466
- AML 30, 36, 75, 187
  - see also leukemia
  - , in children 30
  - , CFC in 187
  - , remission in 30, 36
  - , secondary 360
  - , therapy 30, 36
  - , bone marrow transplantation 62
  - , long-term cultures for 75
- Antibody
  - see also monoclonal antibody
  - , bispecific 367
- Avian
  - , Erythroblastosis Virus E26 461
  - , Erythroid growthfactors 203
- BCDF 123
  - , in leukemic B cells 124
- B cells 333
  - , leukemia 123, 126
  - , BCDF in 124
  - , Ig secretion in 124
  - , malignancy 59
  - , monoclonal antibody against 126
- BCR 138, 145, 160
  - , gene 153
  - , rearrangement 150
- BFU-E 245
- Biological response modifiers 97, 103, 120
- BLV 384, 482
- Bone marrow
  - , antibody purging 63, 68, 86, 89, 92
  - , mismatched donors 82
  - , stromal layer of 177
  - , transplantation
    - , autologous 57, 59, 62, 67, 75, 89, 92
    - , long term cultures for 75
    - , in childhood leukemia 82
- Cancer
  - , clonality 286
  - , human 7, 172
- Carcinogenesis 298
- CD2 337, 339
- Cervical carcinoma 377, 381
- CFU 224, 360
  - , in AML 187
  - , GEMN 245
  - , GM 211, 215
  - , S 218
- Chromosome
  - , breakpoints 145, 160
  - , differentiation genes 138
  - , fragile sites 467
  - , growth factors 139
  - , metal ion regulating genes 139
  - , changes 136
  - , Philadelphia 153, 163
  - , rearrangments 496
  - , translocation 168, 314
- CML 145, 153, 160, 163
  - see also leukemia
  - , philadelphia chromosome in 163
  - , treatment with biological agents 121
- Costimulation with LPS and Ig antibodies 333
- CSF 17
  - , human 240
  - , receptor 234
  - , 1 221
  - , cDNA 221
  - , gene 221
  - , makrophage activation by 224
- C4-1 cell line 379
- Cystic fibrosis 467
- Cytokines 97, 121
- Cytoskeleton
  - , cell membran interaction 195
  - , in leukemic cells 195
- Differentiation
  - , induction 20
  - , of lymphocytes 323
- Drug
  - , resistance 280
  - , screening 279

- EBV 5
- EGF 228
- , receptor 229
- –, regulation 229
- Enzym Immunoassay 368
- Erythrocyt receptor 337
- Erythroleukemic cells 199
- Erythropoetin 201, 245
- Evolution
- , of G3-P-D 513
- , of hemoglobin gene 493
  
- G-CSF 210, 215, 217
- G-3-P-D
- , evolution of 513
- Gene
- , c onc 493
- , hemoglobin 493
- , Ig 315, 320
- , MHC class I 261, 308
- , music and 513
- , proto onc 500
- , rearrangement 263
- , transfer
- –, DNA-mediated 261
- – –, modification of oncogenicity by 261
- Genital papilloma 7, 377
- G-CSF 233, 240, 245
- GM-CSF 233, 240
- , treatment with 121, 213, 215
- Growth factor 17
- , avian erythroid 203
- , chromosome breakpoint 139
  
- Heme- controlled eIF-2 kinase 265, 268
- Hematopoietic progenitor cells 223
- , in AIDS 176
- Hexosaminidase isoenzyme 191
- , in acute leukemia 192
- Histiocytosis
- , malignant 448
- –, sarcoma virus 448
- HIV 5, 43, 395, 407, 436
- , africa sera 432
- , ELISA 430, 434
- , envelop proteins 407, 414
- , false negative ELISA window 411
- , neutralizing antibodies 411, 414
- , nucleotid sequences of 404
- , receptor 389
- , serodiagnosis 430, 434
- , structural proteins 407
- , transfusion-acquired infection 410, 434
- HL-60 274
- HLA=DR 244
- HPV 18, 10, 381
- HTLV
- , I 5, 110, 382, 395
- –, epidemiology of 382
- –, insects and 382
- –, interleukin-2 receptor 395
- –, receptor 398
- –, related viruses 392
- –, replication of 395
- , II 395
- –, receptor 389
- , III
- –, growth in different cell types 436
- –, LTR- target sequences 425
- Human
- , complement for bone marrow purging 87
- , placental conditioned medium 240
- Hybrid hybridoma 367
- Hybridisation
- , in situ 141
  
- Ig
- , genes 315
- –, transcription 334
- , heavy chain gene rearrangments 168
- , secretion in leukemic B-cells 124
- Illegitimate recombination 500
- Immunotoxin
- , in vitro treatment of bone marrow with 57
- In situ Hybridisation 141
- Interferon 105, 121
- Interleukin-2 99
- , receptor 110, 344
- –, promotor of 401
- , treatment with 99, 103, 116
- Interleukin-3
- , autocrine production of 259
- K-562 141
  
- Leukemia
- see also AM1, ALL, CML, T-ALL
- , in children 30, 37, 82
- , cytoskeleton in 195
- , hexosaminidase in 192
- myeloid 21, 30
- , progression 293
- , T-cell 321
- –, line 263
- Leukemogenesis 19
- LAC-cells 116, 350
- Lymphoma 167, 314, 440, 445
- , Baboon 392, 442
- , NHL 39, 57, 172, 441
- –, therapy in children 41
- Lymphotoxin 353
  
- M-CSF 233
- Macrophages
- , activated 352
- –, by CSF-1 224
- , precursor cells 355
- , tumoricidal 352
- Met proto-oncogen 464
- Metastasis
- , biology of 283

MHC class I genes 261, 308  
MNNG 464  
Monoclonal antibodies 69, 87, 91, 92, 103, 265, 269  
–, anti-tac 111  
–, cancer treatment with 103  
–, against leukemic B-cells 126  
–, against myb proteins 490  
Mutation  
–, atavistic 493  
–, point 173  
Myb  
–, proteins 488  
– –, monoclonal antibodies against 490  
myeloid leukemia 19  
Myeloma 360  
Myelopoiesis 274  
  
NK-cells 116, 132, 349, 355  
Neoplasia  
–, lymphoid 248  
Neuroblastoma 116  
Nucleic acid  
–, replication, prebiotic 517  
Nucleoskeleton 299  
  
Oncogene 450, 460, 474, 478, 493, 496  
–, abl 141, 145, 160  
–, alteration in human carcinoma 471  
–, amplification 141  
–, bcl-2 315  
–, met 464  
–, mil 461  
–, myb 488  
–, myc 249, 263, 373, 453, 461, 471  
–, raf 453  
–, ras 173, 259, 449, 471, 478  
– –, and interleukin-3 requirement 259  
–, retroviruses with 462  
–, sarcoma virus 478  
–, virus in 5  
Oncogen  
–, modification of 261  
Osteosarcom 52  
–, intra-arterial chemotherapy 53  
  
Papilloma virus 10, 381  
Philadelphia chromosome 153, 163  
–, positiv ALL 149  
–, translocation 145, 160  
Plasmacytoma 360  
Plasminogen activators 181  
Preleukemia 132  
Promotor 414  
–, of interleukin-2 receptor 401  
Protein tyrosin kinase  
–, abl 149  
–, EGF receptor 229  
–, regulation of T-cell proliferation 345  
  
Proteolysis 183  
Proto  
–, bcl-2 315  
–, onc genes 500  
  
Raf 458  
Ras  
–, oncogene 173, 449  
Rearrangment  
–, chromosome 496  
–, Ig gene 168, 320  
Receptor  
–, down-modulation 237  
–, EGF 229  
Rejection antigens 308  
Replication complex 302  
Retroviruses 503  
– see also viruses  
Risk factors  
–, in AML 30  
RNA  
–, antisense 377  
  
Spectrin 265, 269  
Stem cells 181  
Stromal layer  
–, of bone marrow 177  
  
T11  
–, E rosette receptor 349  
–, TS 337, 340  
T-ALL 57  
–, adult 110, 114  
T-cell  
–, antigen receptor  $\alpha$ -chain 373  
–, differentiation 252, 323  
–, epitopes 324  
– –, interaction with proteins 327  
–, leukemia 321, 372  
–, proliferation 343  
Tac 485  
–, anti-tac monoclonal antibody 110  
Thymic epithelium 252  
Transduction  
–, of myc 373  
Transfection 252, 474  
Transgenic mice 249  
Translation controll 265, 269  
Translocation  
–, chromosomal 168  
–, Philadelphia chromosom 145, 160  
Transcription  
–, complex 300  
–, Ig gene 334  
–, regulation 334  
Tumor  
–, cell differentiation 280  
–, heterogeneity 279, 283  
–, human 453  
–, immunology 351

-, necrosis factor 121, 212, 219, 352  
-, progression 308  
-, specific antigens 308

**Vaccine**

-, onco protein 458  
-, recombinant vaccina virus 362

V-erbB 199

**Virus**

-, Avian erythroblastosis 461  
-, bovine leukemia 384, 482

-, Epstein Barr 5  
- -, like B-lymphotropic herpes 447  
-, HIV 5, 43, 395, 407  
-, HPV 10 381  
- -, in genital papilloma 7  
-, HTLV I 5, 110, 382, 395  
-, human papilloma 377  
-, recombinant vaccina 362  
-, sarcoma virus  
- -, balb 478  
- -, Harvy 478  
-, V-erb 199